207 related articles for article (PubMed ID: 33523098)
1. Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Simmering JE; Welsh MJ; Liu L; Narayanan NS; Pottegård A
JAMA Neurol; 2021 Apr; 78(4):407-413. PubMed ID: 33523098
[TBL] [Abstract][Full Text] [Related]
2. Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.
Sasane R; Bartels A; Field M; Sierra MI; Duvvuri S; Gray DL; Pin SS; Renger JJ; Stone DJ
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 33822767
[TBL] [Abstract][Full Text] [Related]
3. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
5. Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.
Simmering JE; Welsh MJ; Schultz J; Narayanan NS
Mov Disord; 2022 Nov; 37(11):2210-2216. PubMed ID: 36054705
[TBL] [Abstract][Full Text] [Related]
6. α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Choi H; Cheon J; Park JY; Bae JH
J Urol; 2019 Aug; 202(2):362-368. PubMed ID: 30840545
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
[TBL] [Abstract][Full Text] [Related]
8. Risk of Parkinson's disease among users of alpha-adrenergic receptor antagonists: a systematic review and meta-analysis.
Lamichhane P; Tariq A; Akhtar AN; Raza M; Lamsal AB; Agrawal A
Ann Med Surg (Lond); 2024 Jun; 86(6):3409-3415. PubMed ID: 38846867
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Chatziralli IP; Sergentanis TN
Ophthalmology; 2011 Apr; 118(4):730-5. PubMed ID: 21168223
[TBL] [Abstract][Full Text] [Related]
10. [Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Bar-Yosef Y; Mabjeesh NJ; Laufer M; Neulander EZ; Kaver I; Matzkin H
Harefuah; 2008 Jun; 147(6):514-9, 574. PubMed ID: 18693628
[TBL] [Abstract][Full Text] [Related]
11. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Kyprianou N; Chon J; Benning CM
Prostate Suppl; 2000; 9():42-6. PubMed ID: 11056502
[TBL] [Abstract][Full Text] [Related]
12. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults.
Oestreich MC; Vernooij RW; Sathianathen NJ; Hwang EC; Kuntz GM; Koziarz A; Scales CD; Dahm P
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013393. PubMed ID: 33179245
[TBL] [Abstract][Full Text] [Related]
13. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate.
Michel MC; Grübbel B; Taguchi K; Verfürth F; Otto T; Kröpfl D
J Auton Pharmacol; 1996 Feb; 16(1):21-8. PubMed ID: 8736427
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the Pharmacodynamic Uroselectivity of
Quaresma BMCS; Pimenta AR; Santos da Silva AC; Pupo AS; Romeiro LAS; Silva CLM; Noël F
J Pharmacol Exp Ther; 2019 Oct; 371(1):106-112. PubMed ID: 31285236
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of syncope association with α
Ohyama K; Hori Y; Sugiura M
Pharmazie; 2019 Dec; 74(12):755-759. PubMed ID: 31907118
[TBL] [Abstract][Full Text] [Related]
16. Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters.
Kobayashi S; Tomiyama Y; Maruyama K; Hoyano Y; Yamazaki Y; Kusama H
J Smooth Muscle Res; 2009 Aug; 45(4):187-95. PubMed ID: 19783871
[TBL] [Abstract][Full Text] [Related]
17. Alpha blockers for the treatment of benign prostatic hyperplasia.
Lepor H
Rev Urol; 2007; 9(4):181-90. PubMed ID: 18231614
[TBL] [Abstract][Full Text] [Related]
18. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR
Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
[TBL] [Abstract][Full Text] [Related]
19. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
Lee E; Lee C
Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
[TBL] [Abstract][Full Text] [Related]
20. Glycolysis-enhancing α
Weber MA; Sivakumar K; Tabakovic EE; Oya M; Aldridge GM; Zhang Q; Simmering JE; Narayanan NS
NPJ Parkinsons Dis; 2023 Mar; 9(1):32. PubMed ID: 36864060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
